Maintain pressure on reforms to protect NHSRoom temperature version of coagulation factor
Novo Nordisk UK has announced that NovoSeven – its recombinant activated factor VII product available for the treatment of bleeding episodes in people with haemophilia with inhibitors – is now available as a room temperature stable formulation from today onwards. This replaces the previous formulation, which required refrigeration.
This new formulation, which is stable at temperatures up to 25°C, enables patients to administer treatment effectively and quickly after the onset of bleeding in any setting.
Online training units, written and reviewed by experts. Earn two hours' CPD and a personalised certificate for your portfolio.
Subscribers get five FREE learning units and non-subscribers can access each learning unit for £10 + VAT.
Share
Have your say
You must sign in to make a comment.